ArticleHuman vaccines & immunotherapeutics2026
Real-world safety data of human papillomavirus vaccines after marketing in Shandong, China, August 2017-October 2025.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After the Human papillomavirus (HPV) vaccine was listed for use in China in 2017, it has proven to be a safe and cost-effective method for preventing HPV infection. With the increase in vaccination volume, its safety is becoming increasingly important. The safety data from post-marketing can enhance public confidence in vaccines. We collected adverse events following immunization (AEFI) through the Chinese National AEFI Information Management System (CNAEFIs) between August 2017 and October 2025. Vaccination data from the same period were obtained via the Shandong Provincial Immunization Program Information Systems (SDIPIs). A Univariate Poisson regression model was used to explore risk factors associated with HPV vaccine AEFI. Disproportionality analysis was performed to detect abnormal signals related to the HPV vaccine. From August 2017 to October 2025 in Shandong, CNAEFIs received 1056 AEFI cases, with an overall reporting AEFI rate of 7.99 per 100,000 doses. 1008 cases (95.46%) were mild vaccine-related reactions, and 15 cases (1.42%) were rare adverse reactions. Myalgia, induration with a diameter greater than 5 cm, immune thrombocytopenia, and mild reactions such as fatigue, drowsiness, dizziness, and headache were detected as abnormal signals. The reporting AEFI rate of the HPV vaccine in Shandong was low, and the majority of AEFIs were mild cases. The safety profile in post-marketing was good.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.